Clinical efficacy and safety of Janus kinase inhibitors for COVID-19: A systematic review and meta-analysis of randomized controlled trials-Reference-Cited by-同舟云学术

Clinical efficacy and safety of Janus kinase inhibitors for COVID-19: A systematic review and meta-analysis of randomized controlled trials

Published:2021-10 Issue: Volume:99 Page:108027
ISSN:1567-5769
Container-title:International Immunopharmacology
language:en
Short-container-title:International Immunopharmacology

Author:

Chen Ching-Yi,Chen Wang-Chun,Hsu Chi-Kuei^ORCID,Chao Chien-Ming,Lai Chih-Cheng^ORCID

Publisher

Elsevier BV

Subject

Pharmacology,Immunology,Immunology and Allergy

Reference36 articles.

1. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges;Lai;Int. J. Antimicrob. Agents.,2020

2. WHO. https://covid19.who.int/?gclid=CjwKCAjwiLGGBhAqEiwAgq3q_qP6pRDB-zQNmYa-dToZ2Gn8JZqK8egOabpr1yEGJzPtC5y6QvBu6hoCAzYQAvD_BwE Accessed on June 18, 2021.

3. Severe Covid-19;Berlin;N Engl J Med.,2020

4. Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): facts and myths;Lai;J. Microbiol. Immunol. Infect.,2020

5. Neutralizing antibody therapeutics for COVID-19;Hurt;Viruses,2021

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treating dermatomyositis anti‐melanoma differentiation‐associated gene 5 antibody disease. A true rheumatologic urgency;International Journal of Rheumatic Diseases;2023-09-29

2. Therapeutic implications of current Janus kinase inhibitors as anti-COVID agents: A review;Frontiers in Pharmacology;2023-03-20

3. The development of COVID-19 treatment;Frontiers in Immunology;2023-01-26

4. THE EVOLUTION AND TREATMENT OPTIONS OF PATIENTS WITH COVID-19 AND NEUROLOGICAL MANIFESTATIONS – A NARRATIVE REVIEW;FARMACIA;2022-12-26

5. Characteristics of hospitalized patients with COVID-19 during the first to fifth waves of infection: a report from the Japan COVID-19 Task Force;BMC Infectious Diseases;2022-12-12